Home › Compare › PYYIF vs ABBV
PYYIF yields 2.39% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, PYYIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PYYIF + ABBV for your $10,000?
Promotora y Operadora de Infraestructura, S. A. B. de C. V. engages in the construction, operation, maintenance, financing, and promotion of infrastructure projects in Mexico. Its projects include heavy construction projects, such as toll roads, ports, tunnels, dams, bridges, airports, and railways; industrial construction projects comprising petrochemical, industrial, wastewater treatment, and power generating plants; and urban construction projects, such as parking lots, museums, parks, education centers, buildings, water systems, public transportation systems, landfills, and hospitals. The company produces various asphalt concretes; basalt aggregates, including gravel, sand, seal, ballast, hydraulic base, sub-base, and tepetate; and central guard rails for roads, and various other precast concrete materials, as well as exploits stone aggregates. In addition, the company provides services, such as reception, storage, and shipment of goods; hauling or transfer of goods; loading and unloading ships; container filling and emptying; general cargo storage; and mooring and unmooring of ropes, as well as foreign trade merchandise handling, storage, and custody services. Promotora y Operadora de Infraestructura, S. A. B. de C. V. was founded in 1969 and is based in Mexico City, Mexico.
Full PYYIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.